Clinical trials: Severe Asthma
Severe Eosinophilic Asthma
Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)
Benralizumab is a humanised, afucosylated, monoclonal antibody against the interleukin (IL)-5 receptor (IL-5R) α subunit that induces direct, rapid, and near-complete depletion of eosinophils in blood, airway tissue, and bone…
- Trial name
- NCT05271526
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Asthma
Single and Multiple Ascending Dose Study of TD-8236 by Inhalation
This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 3 parts: Part A is a single ascending dose (SAD) study in healthy subjects, Part B is a multiple ascending dose (MAD) study in…
- Trial name
- NCT03652038
- Testing
- TD-8236
- Where
- 2 sites in United Kingdom
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Bronchial Asthma
Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.
Many studies have investigated the efficacy and safety of Intravenous magnesium sulfate and inhaled steroids in addition to the standard treatment for patients with severe asthma attacks.
- Trial name
- NCT02455687
- Testing
- Hi-dose iv MgSO4, Nebulized budesonide, Std-dose iv MgSO4
- Where
- Qatar
- Volunteers
- 240 people
- Sponsor
- Hamad Medical Corporation
Asthma, Severe Eosinophilic Asthma
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe…
- Trial name
- NCT04159519
- Testing
- Symbicort®, Fasenra®, Ventolin®
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Asthma
A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E-RS) in Subjects With Asthma
Asthma and chronic obstructive pulmonary disease (COPD) are chronic inflammatory conditions involving the small airways with airflow limitations resulting from genetic and environmental interactions.
- Trial name
- NCT03344406
- Testing
- Telephonic interviews, E-RS: COPD, Supplemental asthma items
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
GSK3772847, an anti-interleukin (IL)33 receptor monoclonal antibody, is a novel treatment for asthma. This is a phase 2a study which aims to evaluate efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD)…
- Trial name
- NCT03207243
- Testing
- GSK3772847, Fluticasone propionate/salmeterol, Fluticasone propionate
- Where
- 64 sites in United States, Australia and 4 more
- Volunteers
- 165 people
- Sponsor
- GlaxoSmithKline
Severe Asthma
Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
To evaluate the pharmacokinetics, safety and immunogenicity of BAT2606 in healthy China male subjects.
- Trial name
- NCT05576454
- Testing
- Mepolizumab Injection (BAT2606 Injection), Mepolizumab Injection (EU-licensed Nucala), Mepolizumab Injection (US-licensed Nucala)
- Where
- China
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Asthma
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an…
- Trial name
- REIMAGINE (NCT06041386)
- Testing
- Mepolizumab, Spirometry
- Where
- 65 sites in United States, Belgium and 7 more
- Volunteers
- 336 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of Mepolizumab Autoinjector in Asthmatics
This study is aimed to assess the correct real-world use of an autoinjector for the repeat self-administration of mepolizumab SC, so to improve subject / physician convenience and to enable repeat dose self injection themselves…
- Trial name
- NCT03099096
- Testing
- Mepolizumab
- Where
- 38 sites in United States, Australia and 5 more
- Volunteers
- 159 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Asthma
A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic Asthma
1. Eosinophilic asthma, a type 2 immune disorder, often involves the excessive production of type 2 cytokines. 2. Excessive Type 2 cytokines lead to chronic inflammation, airway hyperresponsiveness, and airflow obstruction. 3.
- Trial name
- NCT07250594
- Testing
- AD17002, Formulation buffer
- Where
- Taiwan
- Volunteers
- 126 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Asthma
Adults With Moderate to Severe Asthma
A study to compare the safety and effectiveness of 5 different ways of taking Pulmicort when given to asthma patients aged 12 years and above.
- Trial name
- NCT00642122
- Testing
- Budesonide
- Volunteers
- 900 people
- Sponsor
- AstraZeneca
Asthma
Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids
The study objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids.
- Trial name
- NCT01449162
- Testing
- Masitinib
- Where
- 8 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 420 people
- Sponsor
- AB Science
Asthma
A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma.
- Trial name
- NCT07869043
- Testing
- tilrekimig
- Where
- 3 sites in United States
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Moderate to Severe Persistent Asthma
Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation
This study will evaluate the efficacy, safety of two dose levels of CBP-201 in patients with moderate to severe persistent asthma with Type 2 inflammation.
- Trial name
- NCT04773678
- Testing
- CBP-201
- Where
- 76 sites in United States, China and 3 more
- Volunteers
- 322 people
- Sponsor
- Connect Biopharm LLC
Severe Eosinophilic Asthma
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to…
- Trial name
- STEP (NCT06465485)
- Testing
- Benralizumab
- Where
- 74 sites in China
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Severe Asthma
ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab
This is an observational, Italian multi-center, retrospective cohort study with enrollment visit on patients suffering from severe eosinophilic asthma who started benralizumab in the Sampling Program or as per normal clinical…
- Trial name
- ANANKE (NCT04272463)
- Testing
- No intervention
- Where
- 18 sites in Italy
- Volunteers
- 217 people
- Sponsor
- AstraZeneca
Eosinophilic Asthma
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to…
- Trial name
- NCT01508936
- Testing
- Reslizumab
- Where
- 66 sites in United States
- Volunteers
- 511 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy of lebrikizumab compared with placebo, as measured by the ability of participants to achieve lower daily doses of…
- Trial name
- NCT01987492
- Testing
- Lebrikizumab
- Where
- 71 sites in United States, Australia and 14 more
- Volunteers
- 230 people
- Sponsor
- Hoffmann-La Roche
Severe Asthma
Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)
A retrospective, observational, one arm, single country study, using the computerized database of Maccabi Health Services (MHS).
- Trial name
- SAIL-B (NCT07218172)
- Where
- Israel
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Asthma
Roflumilast Plus Montelukast in Adults With Severe Asthma
This study will evaluate the effect of roflumilast 500 μg once daily (QD) plus montelukast 10 mg QD versus 10 mg montelukast QD alone on predose (trough) prebronchodilator forced expiratory volume in the first second (FEV1).
- Trial name
- NCT01765192
- Testing
- Roflumilast, Montelukast
- Where
- 13 sites in Germany, Hungary and 1 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca